Grzegorz F. Sarek

Grzegorz F. Sarek has a range of experience in the field of gene therapy and research. Grzegorz F. currently serves as the Vice President of Research at EG 427, where they are responsible for building the internal gene therapy capabilities and developing and commercializing HSV-1-based Viral Vector Gene Therapy for unmet treatments for bladder pathologies.

Prior to their current role, Sarek worked as the Director of Gene Therapy and Translational Research at DiNAQOR from June 2020 to August 2021. Grzegorz F. also worked as a Principal Scientist at Roche from April 2018 to March 2019.

In addition, Sarek held positions at Imperial College London and The Francis Crick Institute as a Lab Head and Visiting Group Leader, respectively, from February 2017 to November 2017.

Grzegorz F.'searlier work as a Postdoctoral Fellow at The Francis Crick Institute focused on DNA damage response and telomeres. During this time, they made significant contributions to the field by demonstrating the role of TRF2 shelterin subunit in recruiting RTEL1 helicase to telomeres for t-loop unwinding and studying the regulation of the RTEL1-TRF2 interaction using various techniques such as phosphoproteomics, crystallography, and NMR.

Grzegorz F. Sarek pursued their education in the field of Oncology and Cancer Biology at the University of Helsinki. From 2003 to 2011, they completed their PhD studies at the university, dedicating their research to advancing knowledge in this specialized area.